Allchem Lifescience

What Allchem Lifescience does

Allchem Lifescience Limited is a Vadodara, India-based manufacturer of active pharmaceutical ingredient (API) intermediates, specialty chemicals, and contract manufacturing services serving global pharmaceutical, agrochemical, electrochemical, and biotechnology customers. Founded in 2003 by Bipin Patel as a proprietorship (Allchem Laboratories), the company operates from a single integrated facility with 1,134 KL of total manufacturing capacity across 11 production blocks, including one of India's largest dedicated hydrogenation facilities (60 KL with 14 gas induction reactors) and a separate high vacuum distillation plant (33 reactors, 30 KL). The product portfolio spans large-volume API intermediates (e.g., Quetiapine, Cetirizine, Terbinafine, Mirtazapine), mid-volume intermediates (e.g., Rifapentine, Lurasidone, Aripiprazole), specialty chemicals (piperazine derivatives, cycloalkane derivatives), custom synthesis, and contract manufacturing (CDMO) under exclusive CDA arrangements.

The business operates a B2B direct sales model targeting pharmaceutical API manufacturers globally, with revenue generated from one-time sales of intermediates, specialty chemicals, and project-based custom synthesis contracts. Pricing is quote-based and not publicly disclosed; multi-year supply agreements underpin customer relationships. Marketing channels include participation in CPHI trade shows across India, Europe, and Japan, a corporate website with quote-request functionality, and a LinkedIn presence. The company serves four primary verticals — pharmaceutical (core), agrochemical, electrochemical, and biotechnology — with geographic reach spanning India, Europe, Japan, China, Korea, USA, Brazil, Canada, and Africa.

The company achieved ₹100 crore turnover in FY2022, scaled equipment capacity from 36 KL in 2013 to 1,134 KL in 2024 (31x expansion), completed a successful US FDA audit in 2024 with EIR receipt, holds cGMP (ICH Q7), ISO 9001/14001/45001 certifications, and filed a Draft Red Herring Prospectus with SEBI in March 2025 for an ₹905 crore IPO. Allchem is promoter-controlled by Bipin Patel (Managing Director, 23 years of pharmaceutical experience) and Kantilal Patel (Director-Technical, 45 years of engineering experience).

Name

Allchem Lifescience

Legal name

Allchem Lifescience Limited

Website

https://allchemlifescience.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

Allchem Lifescience is a Vadodara-based manufacturer of API intermediates, specialty chemicals, custom synthesis, and CDMO services, serving pharmaceutical, agrochemical, electrochemical, and biotechnology customers globally across India, Europe, the US, and Asia.

Ownership category

akta.pro rank

Product category

API Intermediates Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Other Chemical Product and Preparation Manufacturing (3259)

SIC

Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Custom Intermediates & Advanced Intermediates Manufacturing (HLAGAHAH), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• API intermediates manufacturing
• Specialty chemicals production
• Custom synthesis services
• Contract manufacturing CDMO
• Pharmaceutical chemical manufacturing

Headquarters

HQ city

Vadodara

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Intermediates Manufacturing: B2B manufacturing and supply of Active Pharmaceutical Ingredient intermediates to pharmaceutical companies. Revenue generated from sale of large volume and mid volume API intermediates. Products include intermediates for Quetiapine, Aripiprazole, Terbinafine, Domperidone, and 20+ other APIs.
2. Specialty Chemicals: Manufacturing and supply of specialty chemicals including piperazine derivatives, hydrogenation-based products, and cycloalkane derivatives for pharmaceutical, agrochemical, and industrial applications.
3. Custom Synthesis: Custom synthesis services for difficult-to-source API intermediates and specialty chemicals, primarily serving direct innovators with very limited competition. Revenue from development and manufacturing of unique molecules per customer specifications.
4. Contract Manufacturing (CDMO): Contract manufacturing under exclusive CDA (Contract Development Agreement) arrangements, representing approximately 10% of business focus. Provides end-to-end manufacturing services for pharmaceutical intermediates.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Allchem Lifescience manufactures and supplies Active Pharmaceutical Ingredient (API) intermediates and specialty chemicals for the pharmaceutical, agrochemical, electrochemical, and biotechnology industries. The company's core product lines include large-volume and mid-volume API intermediates (e.g., Quetiapine, Aripiprazole, Terbinafine, Domperidone), specialty chemicals (piperazine derivatives, hydrogenation-based products, cycloalkane derivatives), and complementary custom synthesis and contract manufacturing (CDMO) services.

Product overview

Allchem Lifescience Ltd. is a Vadodara-based pharmaceutical and specialty chemicals manufacturer offering a portfolio of products centered on API intermediates and specialty chemicals. The core product lines include API Intermediates (split into Large Volume and Mid Volume categories) and Speciality Chemicals (encompassing Piperazine Derivatives, Hydrogenation-Based Products, and Cycloalkane Derivatives). These are complemented by Custom Synthesis services for difficult-to-source compounds and Contract Manufacturing (CDMO) services. The company operates multiple production plants with a total capacity of 1,134 KL across 11 production blocks, with specialized hydrogenation and high-vacuum distillation facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• API Intermediates (Large Volume)

Quantifiable outcome

• Manufacturing capacity grew from 36 KL (2013) to 1,134 KL (2024), representing 31x capacity expansion over 11 years
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Novan Trade Chem Pvt. Ltd.coreOthersWholly-owned subsidiary of Allchem Lifescience Ltd. Included in investor disclosures under 'Subsidiary, Associates & Group Companies'. The subsidiary represents corporate structure consolidation within the Allchem group.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Jubilant Pharmova: Indian integrated pharma company with substantial API, intermediates, and CDMO operations. Overlapping intermediates portfolio and CDMO services make it a relevant scale-comparable peer.
• Granules India: Indian API and finished-dose manufacturer with intermediates capabilities. Comparable in API intermediates focus but vertically integrated further into finished dosages.
• Piramal Pharma Solutions: Global CDMO with strong India presence offering API and intermediates contract manufacturing. Relevant peer given Allchem's CDMO ambitions, though Piramal operates at substantially larger scale and broader scope.
• Laurus Labs: Major Indian API and intermediates manufacturer with growing CDMO business. Comparable in API intermediates but operates at significantly larger scale and broader therapeutic coverage.
• Divi's Laboratories: One of India's largest API and intermediates manufacturers with significant export business to regulated markets. Operates at considerably larger scale but shares intermediates/contract manufacturing orientation.

Direct peers

• Neuland Laboratories: Indian API and intermediates manufacturer with custom synthesis and contract manufacturing services. Comparable in size, product mix, and customer focus on regulated generic APIs.
• Suven Pharmaceuticals: Indian CDMO focused on API intermediates, custom synthesis, and contract manufacturing for global pharma. Closely comparable in business model and product positioning.
• Dishman Carbogen Amcis: Indian-origin CDMO specializing in API intermediates, advanced intermediates, and contract manufacturing with strong custom synthesis franchise. Directly comparable CDMO/intermediates peer with similar customer base.
• Hikal Ltd: Indian manufacturer of API intermediates, custom synthesis, and CDMO services for pharmaceuticals and agrochemicals. Most direct comparable in scale, geography (India), and product mix of intermediates plus specialty chemicals.
• Aether Industries: Indian specialty chemicals and intermediates manufacturer serving pharmaceutical and agrochemical customers with custom synthesis capabilities. Comparable in product portfolio, custom-synthesis orientation, and India-based manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/allchem-lifescience-pvt-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allchem Lifescience